

Anti-Gastric Inhibitory Peptide (GIP)**Mouse monoclonal antibody**

Subclass:

Clone: 32

CAT. NO.

ABS 054-26

SPECIFICITY ABS 054-26 binds human GIP (1-42).**IMMUNOGEN** Synthetic human gastric inhibitory polypeptide**TESTED APPLICATIONS** ELISA**SPECIES REACTIVITY (POSITIVE)** Human**SPECIES REACTIVITY (NEGATIVE)** Not determined**EPITOPE SPECIFICITY** Not determined

PRESENTATION**Content:** Available in 200 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.**Preparation:** Protein-A purified**Form:** Liquid**Solvent:** 0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide**Storage:** 2-8°C

APPLICATION**ELISA:**

ABS 054-26 (as capture antibody) forms a sandwich ELISA pair with ABS 054-24B (as biotinylated detection antibody) for measuring GIP. Detection limit obtained with our non-optimized buffer system is up to 4 ng/mL of GIP (1-42). This pair seems to be also more sensitive than pair ABS 021-04 / ABS 054-24B with our non-optimized buffer system.

TARGET

Human gastric inhibitory polypeptide (GIP) is a 42 amino acid peptide belonging to the glucagon-secretin family of peptide hormones. It is secreted by endocrine cells in the duodenal mucosa and stimulates glucose-dependent insulin secretion as well as GLP-1 release from more distal endocrine (L) cells in the intestinal mucosa. GIP shows amino-acid sequence similarities to glucagon, GLP-1 and GLP-2 (from approximately 50% identity for glucagon to 30% identity for GLP-2).

REFERENCES**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.